Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products... Show more
Establishment Labs Holdings is a Costa Rica-based medical technology company focused on women's health, breast aesthetics, and breast reconstruction, best known for its Motiva implant portfolio. Its third-quarter report matters because it tests whether the company can convert rapid U.S. market-share gains into improving profitability and cash generation. Heading into the print, investors were watching top-line momentum, gross margin trajectory, and the path toward positive free cash flow. The company entered the quarter having raised guidance in consecutive periods, and the U.S. launch of Motiva and the Preservé minimally invasive platform remained the central growth story. Results delivered record-scale revenue growth and a long-awaited cash-flow milestone, even as one-time charges pressured the reported bottom line.
For the third quarter ended September 30, 2026, Establishment Labs reported revenue of $72.0 million, an increase of 33.9% from $53.8 million in the prior-year period and above the consensus estimate of approximately $66.6 million. U.S. revenue surged 119% to $26.0 million, representing 36.1% of total revenue, while revenue outside the United States rose 9.7% to $46.0 million. The minimally invasive platform generated about $9 million in revenue, up 124% year over year.
GAAP net loss narrowed to $10.7 million, or $0.35 per share, compared with a loss of $11.1 million, or $0.38 per share, a year earlier. The per-share result came in below the consensus estimate of a $0.27 loss, driven largely by below-the-line interest expense and one-time litigation, restructuring, and inventory charges. GAAP gross margin was 69.1%, while adjusted gross margin improved to 70.8%, up 70 basis points year over year on a favorable U.S. and minimally invasive product mix.
Adjusted EBITDA increased to $6.4 million, or 8.9% of revenue, from $1.2 million in the prior-year quarter. The company generated $7.7 million in operating cash flow and $5.1 million in free cash flow, marking its first positive free-cash-flow quarter. Management also raised full-year 2026 revenue guidance to more than $274 million and reiterated an expectation for roughly 25% revenue growth in 2027.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Establishment Labs, the AI Screener offers a structured way to monitor sector momentum and identify comparable opportunities. Consider exploring the AI Screener to refine your own watchlists and research workflow.
The market's focus was split between the company's accelerating U.S. growth and the headline earnings-per-share miss. While revenue beat expectations by roughly 8%, the $0.35 per-share loss fell short of the consensus $0.27 loss, reflecting interest expense on the company's note payable and one-time litigation, restructuring, and inventory-related charges. Investors appeared to weigh the quality of the operating results more heavily, as adjusted EBITDA expanded, operating leverage improved, and the company delivered its first positive free-cash-flow quarter. The third consecutive full-year revenue guidance increase, along with a reaffirmed expectation for about 25% revenue growth in 2027, reinforced the view that demand momentum remains intact. Sentiment remains balanced against thinner profitability in OUS distributor channels and the company's relatively lean balance sheet.
Looking ahead, investors will likely track whether Establishment Labs can sustain its U.S. adoption momentum while converting that growth into durable profitability and cash generation. Management pointed to an 85% quarter-over-quarter reorder rate among U.S. accounts and more than 2,100 active accounts, suggesting utilization within the existing surgeon base is becoming the key growth lever.
Regulatory and product milestones will also be closely watched. The October FDA (U.S. Food and Drug Administration) approval of additional Motiva implant sizes is expected to be commercially available before year-end, and management is working toward a reconstruction approval targeted for late 2026 or early 2027. The company also plans to expand sizes for its Mia and Preservé minimally invasive products globally.
On the financial side, the full-year adjusted gross margin guidance of approximately 70.7% reflects a higher mix of lower-margin OUS distributor sales, a dynamic worth monitoring. The company reiterated full-year adjusted operating expense guidance of $195 million to $200 million. With the balance sheet still carrying a substantial note payable against $75.8 million in cash, sustained free-cash-flow generation will remain a focal point for investors assessing the company's path toward self-funding growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of medical products
Industry MedicalNursingServices